A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

NCT02717624 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Acalabrutinib in combination with BR
DRUG: Acalabrutinib in combination with VR

Sponsor

Acerta Pharma BV

Collaborators

[object Object]